BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $36
Pfizer Analyst Ratings
Erste Group Initiates Pfizer(PFE.US) With Hold Rating
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Pfizer Analyst Ratings
Citigroup Adjusts Price Target on Pfizer to $30 From $28, Maintains Neutral Rating
Pfizer Analyst Ratings
Daiwa Securities Upgrades Pfizer to Outperform From Neutral, Adjusts Price Target to $34 From $28
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Argus Research Maintains Pfizer(PFE.US) With Hold Rating
Pfizer Price Target Maintained With a $45.00/Share by Cantor Fitzgerald
Pfizer Price Target Raised to $31.00/Share From $30.00 by UBS
Pfizer Analyst Ratings
DZ BANK AG Maintains Pfizer(PFE.US) With Buy Rating
BofA Securities Maintains Pfizer(PFE.US) With Hold Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $32 to $45
Cantor Fitzgerald Sticks to Its Buy Rating for Pfizer (PFE)
Truist Financial Keeps Their Buy Rating on Pfizer (PFE)
Morgan Stanley Raises Price Target on Pfizer to $31 From $29, Keeps Equalweight Rating